MAP Pharmaceuticals Provides Update on LEVADEX® Program
MOUNTAIN VIEW, Calif., April 12, 2012 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today provided an update on LEVADEX®, the Company's investigational orally inhaled drug for the potential acute treatment of migraine in adults.
- The Company submitted a request to the U.S. Food and Drug Administration (FDA) for a meeting to discuss the Complete Response letter received on March 26, 2012. The Company announced that the FDA has scheduled a meeting with the Company, to occur in the second quarter.
- On April 3, 2012, the United States Patent and Trademark Office (USPTO) issued to the Company U.S. Patent No. 8,148,377, titled "Method of Therapeutic Administration of DHE to Enable Rapid Relief of Migraine While Minimizing Side Effect Profile." This new patent, which expires in 2028, is the third in a series of patents issued to the Company relating to the pharmacokinetics of LEVADEX. The new patent results from the Company's discovery that dihydroergotamine (DHE) can be administered to achieve pharmacokinetic profiles of DHE that result in rapid efficacy while minimizing side effects that are typically seen with other migraine drugs.
"We are pleased that the FDA has scheduled a meeting with us to discuss the issues contained in the Complete Response letter for LEVADEX," said Timothy S. Nelson, president and chief executive officer of MAP Pharmaceuticals. "We continue to work closely together with our partner, Allergan, as we seek to resolve the issues in the Complete Response letter as quickly as possible."
About MAP Pharmaceuticals
MAP Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing new therapies to address undermet patient needs in neurology. The Company is developing LEVADEX®, an orally inhaled investigational drug for the poten